for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brickell Biotech Inc

BBI.N

Latest Trade

0.90USD

Change

-0.01(-1.31%)

Volume

6,725

Today's Range

0.89

 - 

0.92

52 Week Range

0.61

 - 

4.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.91
Open
0.91
Volume
6,725
3M AVG Volume
36.92
Today's High
0.92
Today's Low
0.89
52 Week High
4.55
52 Week Low
0.61
Shares Out (MIL)
27.27
Market Cap (MIL)
24.78
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q2 2020 Brickell Biotech Inc Earnings Release

Latest Developments

More

Brickell Biotech Posts Quarterly Loss Per Share $0.45

Brickell Biotech Issues Prospectus Related To Resale Of Common Stock By Lincoln Park Capital Fund, Llc

Brickell Biotech Q4 Revenue $700,000 Versus $2.5 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brickell Biotech Inc

Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Industry

Biotechnology & Drugs

Contact Info

5777 Central Ave Ste 102

BOULDER, CO

80301-2870

United States

+1.720.5054755

https://brickellbio.com/

Executive Leadership

Reginald L. Hardy

Chairman of the Board, Co-Founder

Robert B. Brown

Chief Executive Officer, Director

Andrew D. Sklawer

Co-Founder, Chief Operating Officer, Secretary

R. Michael Carruthers

Chief Financial Officer

Jose Breton

Chief Accounting Officer, Controller

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
4.53
Price To Book (MRQ)
1.49
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-93.85
Return on Equity (TTM)
-78.68

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up